Healthcare
Clinuvel Pharmaceuticals Ltd(CLVLF)
Live Price
Offline$6.10
+0.00% today
1Y Change
-15.51%
Window
Jun 25, 2025 β Jun 17, 2026
- Market Cap
- $480.00M
- Revenue Growth
- +7.8%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.5%
Coverage: 246 bars Β· Jun 25, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Clinuvel Pharmaceuticals Ltd (CLVLF) is a Healthcare stock with a market cap of $480.00M and listed on OTC. The stock last traded around $6.10 and down 15.5% across the available one-year price window (Jun 25, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of +7.8%, EPS growth of 0.0%, a dividend yield of 0.5%. What stands out right now is revenue +7.8%, EPS 0.0%, free cash flow +29.6% with operating margin 39.4% and ROIC 11.1%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 14.7 and price/sales 5.0. Stock Foundry combines CLVLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.8% vs +7.6% peer median
Operating Margin
Above sector median
+39.4% vs +19.4% peer median
P/E
Below sector median
14.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 25, 2026 with an EPS surprise of -29.5% and a revenue surprise of -0.9%.
The setup is mixed rather than one-directional
Revenue is +7.8% and EPS is 0.0%, while operating margin sits near 39.4%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 1, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 25, 2026 | -29.5% | +0.0% | +0.0% | +0.0% |
2025 Aug 28, 2025 | +55.4% | +0.0% | -12.4% | -8.6% |
2025 Feb 26, 2025 | +29.0% | +0.0% | +0.0% | +10.8% |
Benchmark Edge
CLVLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLVLF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLVLF Max Drawdown
-29.07%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLVLF and SPY.
Company Overview
Clinuvel Pharmaceuticals Ltd
OTC
Clinuvel Pharmaceuticals Ltd is a global specialty biotechnology company dedicated to the development and commercialization of innovative treatments for rare and severe medical conditions. The company focuses particularly on disorders related to light exposure, genetic, metabolic, and systemic diseases that often have limited treatment options. Its flagship product, SCENESSE (afamelanotide), is the first approved systemic photoprotective therapy, designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP)βa rare genetic disorder characterized by severe pain on light exposure. SCENESSE is available in multiple international markets, including Europe, the United States, and Australia, reflecting Clinuvelβs established global footprint. Beyond its core pharmaceutical products, the company is engaged in developing a broader pipeline that includes treatments for additional patient groups and photoprotective solutions, such as PRENUMBRA and NEURACTHEL, and cosmetic healthcare innovations through its PhotoCosmetics division. Headquartered in Melbourne, Australia, Clinuvel Pharmaceuticals Ltd plays a significant role in the healthcare sector, contributing novel therapies that address underserved patient populations while supporting broader advancements in photoprotection and genetic disorder management.
- Leadership
- Dr. Philippe Jacques Wolgen M.B.A., M.D.
- Street Address
- 535 Bourke Street, Level 22
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, Australia
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 14.7
- EV/EBITDA
- 10.7
- Price/Sales
- 5.0
- Price/Book
- 1.9
Growth
- Revenue
- +7.8%
- EPS
- 0.0%
- Free Cash Flow
- +29.6%
Profitability
- Gross Margin
- 63.7%
- Operating Margin
- 39.4%
- Net Margin
- 33.8%
- ROE
- 13.3%
- ROIC
- 11.1%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 14.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.